Dr. Christopher B. Griffith, M.D.
Medical Genetics (Clinical Genetics (M.D.) Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 20
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Indiana University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Genetics (M.D.) Physician primary
FL license ME128186 · IN license 01063607A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Lee Health System Inc (1,428 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 20
- Services billed
- 24
- Patients’ average age
- 65
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Galafold (migalastat hcl) | 34 |
| Fabrazyme (agalsidase beta) | 24 |
| Diphenhydramine Hcl | 14 |
| Xenpozyme (olipudase alfa-rpcp) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $5,841 in research payments for these studies, mostly to the institutions running them.
- Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease
Amicus Therapeutics, Inc. - Fabry Disease Registry & Pregnancy Sub-registry
Sanofi US Services Inc. · Recruiting · NCT00196742 - Mucopolysaccharidosis I (MPS I) Registry
Sanofi US Services Inc. · Completed · NCT00144794
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.